• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • Insight
11 min read 16th March 2022

The NICE Health Technology Evaluation Manual: A Fresh Perspective Needed?

We live in a world facing many interrelated challenges, and the choices we make about allocating public sector resources have never been more consequential. The perspective taken in an economic evaluation determines the costs and outcomes included in that evaluation…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

We live in a world facing many interrelated challenges, and the choices we make about allocating public sector resources have never been more consequential. The perspective taken in an economic evaluation determines the costs and outcomes included in that evaluation and therefore shapes resource allocation and access to new treatments. In this blog, we review the (lack of) changes to NICE’s manual to include elements of a ‘societal perspective’.

This blog post is the fourth in a series on the new National Institute for Health and Care Excellence (NICE) health technology evaluation manual. Each post provides a critical discussion on a particular topic, including the expected implications of the changes (or lack thereof) in the manual; what is still missing; and what further research is needed.

We live in a world facing many challenges – from the devasting effect of COVID-19 on health systems worldwide to climate change and political instability. How we allocate public sector resources to address these competing but often interrelated challenges has never been more consequential. The perspective taken in an economic evaluation determines the costs and outcomes which are included in that evaluation, and therefore shapes resource allocation and access to new treatments. In this blog, we review the changes to NICE’s health technology evaluation manual to include elements of a ‘societal perspective’.

What is a societal perspective?

A healthcare system perspective focuses solely on the health effects produced by an intervention, and the costs to the healthcare system of delivering that intervention. A societal perspective, in the simplest terms, means that all effects and costs which matter to society are included – regardless of what form these take and where they accrue. The societal costs which have received the most attention in the literature are the financial outlays (e.g. for transport to receive healthcare) and productivity costs (the hours of work lost or gained as a result of treatment) borne by patients and their families and carers (Garrison et al., 2018). In terms of societal effects, arguments have been made for expanding the definition of health to include not just changes in quality and length of life but, for example, improvements in the wellbeing and life satisfaction of patients and carers that may not be adequately captured by traditional quality of life measures  (Cylus and Smith, 2020). A societal perspective should also include effects which matter to society but accrue in other sectors, for example the effect of a treatment to reduce alcohol misuse on crime (Walker et al., 2019) or children’s ability to attend school regularly.

What perspective does NICE take?

The NICE Charter states than NICE’s key role is “to provide an independent assessment of the value of existing and new treatments and interventions for the system”. They do this “to benefit the population as a whole and to improve and ensure equity of access to all members of society.” Yet the new NICE manual states that health technologies should be assessed from an NHS and Personal Social Services (PSS) perspective. The only societal effects that are included are:

  • Carers health effects, which can be included expressed in quality-adjusted life years – although challenges remain as explained in our previous blog.
  • Effects in other sectors (i.e., non-NHS government bodies), which can be included only if they are substantial.
  • Effects on productivity, which can be included if critically important to the value of the technology. This is the only notable change since the previous NICE manual.

The last two effects are considered additional and should be presented separately from the main analysis, which always takes a narrow NHS/PSS perspective. In addition, no guidance was provided on how they should be measured or presented, which will make their consideration in decision-making challenging

What is the case for a societal perspective?

A societal perspective has the advantage of capturing a full range of the consequences of interventions – thereby better reflecting the broad public interest (Neumann et al., 2016). In a world of competing demands for public resources, this can help allocate resources to the most socially valuable interventions, as well as sending signals to innovators to invest in R&D of projects which are expected to maximise social value (Neumann et al., 2021).

Proponents also argue that taking a societal perspective in the assessment of health technologies is an important step towards optimal allocations of public money across government sectors (e.g. Jönsson, 2009; Johannesson et al., 2009). An OHE paper highlights the current gaps and inconsistencies in the approaches used to assess value for money across public sector activities.

What are the challenges of taking a societal perspective?

There are significant empirical and methodological challenges to the implementation of a societal perspective when assessing the value of health technologies. In particular, how to measure and value multiple, potentially overlapping effects remains controversial. However, there are many societal effects which can already be incorporated into standard calculations of a cost-per-QALY, including effects on carers’ quality of life; productivity; and unpaid and informal care (Neumann et al., 2016). Indeed, inclusion effects on carers quality of life is part of NICE HTA appraisals, and inclusion of productivity costs and effects is standard in the Netherlands and was until recently in Sweden (TLV, 2020; Versteegh, Knies and Brouwer, 2016).

An additional concern is that, by including productivity effects, a societal perspective would bias allocation of health resources towards working age populations. This is because technologies which lead to greater increases in a patient populations’ working hours would be valued more highly. However, is important to note that no perspective is free from equity concerns – and that methodological solutions exist to address these. The healthcare system perspective, for instance, tends to redistribute health away from people who have low capacity to benefit from treatment, or from the elderly who have shorter life spans (Soares, 2012). How far the new NICE manual addresses equity concerns is the topic of our next blog in this series.  

What should happen next?

It is promising that the new NICE manual now allows for productivity effects to be included (in some circumstances) in the evaluation of new healthcare interventions. However, these changes do not go far enough. The incentives for developers to submit evidence on productivity and other societal costs and effects remain relatively weak given the lack of guidance on which evidence should be collected and how this should be considered in decision-making. In future methods reviews and changes, we urge NICE to give full consideration to their choice of perspective. This is a debate which raises fundamental questions about what matters to our society and the role of health and social care within it, and surely merits a case for change.

 

Related research

Cubi-Molla, P., Buxton, M. and Devlin, N., 2021. Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere? Applied Health Economics and Health Policy, 19(5), pp.635–644. 10.1007/s40258-021-00648-2.

Cubi-Molla, P., Mott, D., Henderson, N., Zamora, B., Grobler, M. and Garau, M., 2021. Resource Allocation in Public Sector Programmes: Does the Value of a Life Differ Between Governmental Departments? [Research Paper] London: Office of Health Economics. Available at: https://www.ohe.org/publications/resource-allocation-public-sector-programmes-does-value-life-differ-between

  • Health Technology Assessment…
  • Value, Affordability, and…
  • NICE

Related Insights

Blog 4
  • Insight
  • October 2022

The Economics of Antibiotics – Part 4: What Does the Antibiotics Market of the Future Look Like?

Read more
Slide3
  • Insight
  • October 2022

The Economics of Antibiotics – Part 3: Creating a Healthy Global Market for New Antibiotics

Read more
Sleepio_Adobe_montblanca-e1673970227875
  • Insight
  • May 2022

Sleepio: Lessons from the Frontier of Digital Therapeutics

Read more
3D Isometric Flat Vector Conceptual Illustration of Health Equit
  • Insight
  • April 2022

Let’s talk about (health) inequalities

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!